



cells) and HCs (0.025 pg/mL/10000 cells) at 12.5 dpc. (C) The data from Figure 2A with 2B were combined to compare EPO and SCF protein expression in each fraction sorted from fetal liver. EPO protein expression was highest in HBs. (D-F) Liver sections were prepared from ICR mouse embryos at 12.5 dpc and stained with Dlk-1 (green), EPO (red) and TOTO-3 (blue) (D); Lyve-1 (green), SCF (red) and TOTO-3 (blue) (E); and Dlk-1 (green), SCF (red) and TOTO-3 (blue) (F). Arrowheads show co-localization of the antigens, respectively. Samples were observed under confocal microscopy. EPO was primarily expressed in HBs expressing Dlk-1, whereas SCF was more widely expressed in FL. Original magnification is 40x. (D-F)

**Fig. 3.** Phenotypic analysis of FL in *Map2k4*<sup>-/-</sup> mouse embryos. (A) Expression of *EPO* and *SCF* was examined by real-time PCR in *Map2k4*<sup>-/-</sup> fetal liver (FL). Expression levels of both *EPO* and *SCF* were down-regulated in *Map2k4*<sup>-/-</sup> FL relative to wild-type FL. (B) Liver sections were made from both *Map2k4*<sup>-/-</sup> and wild-type mouse embryos at 12.5 dpc, stained with c-Kit (green), Ki-67 (red) and TOTO-3 (blue), and observed under confocal microscopy. The number of Ki-67 positive cells in a field decreased in *Map2k4*<sup>-/-</sup> FL compared to wild-type FL. Original magnification is 40x. (C) Single cell suspensions were obtained from *Map2k4*<sup>-/-</sup> and wild-type FL at 12.5 dpc and the number of living cells was counted after Trypan Blue staining. Significant decreases in the number of *Map2k4*<sup>-/-</sup> FL cells were observed compared to wild-type FL cells.


# Figure 1A




# Figure 1B




# Figure 1C




**Figure 2A**




**Figure 2B**




**Figure 2C**




**Figure 2D**





**Figure 2E**




**Figure 2F**



# Figure 3A




# Figure 3B



c-Kit Ki-67 TOTO-3



# Figure 3C



# Variation in Mesodermal and Hematopoietic Potential of Adult Skin-derived Induced Pluripotent Stem Cell Lines in Mice

Tomoko Inoue · Kasem Kulkeaw · Satoko Okayama ·  
Kenzaburo Tani · Daisuke Sugiyama

© Springer Science+Business Media, LLC 2011

**Abstract** Induced pluripotent stem cells (iPSCs) are a promising tool for regenerative medicine. Use of iPSC lines for future hematotherapy will require examination of their hematopoietic potential. Adult skin fibroblast somatic cells constitute a source of iPSCs that can be accessed clinically without ethical issues. Here, we used different methods to compare mesodermal and hematopoietic potential by embryoid body formation of five iPSC lines established from adult mouse tail-tip fibroblasts (TTFs). We observed variation in proliferation and in expression of genes (*Brachyury*, *Tbx1*, *Gata1*, *Klf1*, *Csflr*) and proteins (Flk1, Ter119 and CD45) among TTF-derived lines. 256H18 iPSCs showed highest proliferation and most efficient differentiation into mesodermal and hematopoietic cells, while expression levels of the pluripotency genes *Oct3/4*, *Sox2*, *Klf4* and *Nanog* were lowest among lines analyzed. By contrast, the 212B2 line, transduced with *c-Myc*, showed lowest proliferation and differentiation potential, although expression levels of *Oct3/4*, *Sox2* and *Klf4* were highest. Overall, we find that mesodermal and hematopoietic potential varies among iPSCs from an identical tissue source and that *c-Myc* expression likely underlies these differences.

**Electronic supplementary material** The online version of this article (doi:10.1007/s12015-011-9249-3) contains supplementary material, which is available to authorized users.

T. Inoue · K. Kulkeaw · S. Okayama · D. Sugiyama (✉)  
Department of Hematopoietic Stem Cells, SSP Stem Cell Unit,  
Kyushu University Faculty of Medical Sciences,  
Station for Collaborative Research 1 4F,  
3-1-1 Maidashi, Higashi-Ku, Fukuoka 812–8582, Japan  
e-mail: ds-mons@yb3.so-net.ne.jp

T. Inoue · K. Tani  
Department of Molecular Genetics,  
Medical Institute of Bioregulation, Kyushu University,  
Fukuoka 812–8582, Japan

**Keywords** Induced pluripotent stem cells · Tail-tip fibroblasts · Embryoid body · Mesodermal induction · Hematopoietic potential

## Introduction

Hematopoietic stem cells (HSCs) are already in use for transplantation therapy for hematological diseases. However, problems associated with HSC transplantation remain, such as a shortage of donors or immunoreactivity caused by HLA mismatching (rejection and graft versus host disease (GVHD)). To overcome these issues, induced pluripotent stem cells (iPSCs) could serve to generate autologous HSCs without the need for a donor. iPSCs have been established from various somatic cells by forced expression of defined factors [1, 2]. These cells display properties similar to embryonic stem cells (ESCs) in terms of differentiation capacity into various cell types, teratoma formation in immuno-deficient mice, and generation of chimeric mice with germ line transmission [3]. Therefore, iPSC technology could enable us to generate cells for clinical purposes without an embryonic source or a donor [4, 5]. Generally, *Oct3/4*, *Sox2*, *Klf4*, and *c-Myc* are retrovirally transduced into somatic cells to initiate reprogramming and establish iPSC lines. Since both expression of the *c-Myc* oncogene and retroviral infection are associated with malignancy, investigators have devised reprogramming protocols lacking *c-Myc* transduction [6] or avoiding use of non-integrated viral vectors [7] or plasmids [8] for gene delivery. Various novel approaches, including combining transcription factors and reporters, have been employed to reprogram various types of somatic cells, such as mouse embryonic fibroblasts (MEFs), adult fibroblasts, pancreatic  $\beta$ -cells, hepatocytes, gastric epithelial cells, B cells, and CD34<sup>+</sup> cord blood cells

[9–11]. Among these cell types, adult skin fibroblasts are a desirable potential source of somatic cells, since they can be clinically accessed without ethical problems. To help devise future clinical transplantation therapies, it is necessary to determine which iPSCs derived from tail-tip fibroblasts (TTFs) (adult skin fibroblasts in mice) are most fit to generate HSCs.

Previously, we reported variation in hematopoietic potential among several iPSC lines, regardless of the source of somatic cells [12]. This observation suggested that variation in hematopoietic potential could occur among TTF-derived iPSCs. To address this issue, we analyzed mesodermal and hematopoietic potential in five TTF-derived iPSC lines established using different transcription factors (*Oct3/4*, *Sox2* and *Klf4* with or without *c-Myc*) or reporter genes (*DsRed* or *GFP*). We demonstrate that both mesodermal and hematopoietic cell number and expression of mesoderm and hematopoietic cell differentiation markers varies among the five lines. Interestingly, 212B2 iPSCs, the only line created via *c-Myc* transduction, exhibited lower capacity to differentiate into mesodermal and hematopoietic cells compared than did the other four iPSCs.

## Materials and Methods

### iPSCs Maintenance

We used the five lines of tail-tip fibroblast (TTF)-derived iPSCs, such as 256H13, 256H18, 212B2, 212D1 and 335D1, which were kindly provided by Dr. Shinya Yamanaka (Kyoto University). These iPSCs were established by “separate method” as previously described [6]. Briefly, pMX-Oct3/4, pMX-Klf4, pMX-Sox2, and/or pMX-c-Myc plasmids were separately transfected into separate dishes of Plat-E cells using Fugene 6 reagent (Roche Applied Science, Indianapolis, IN). Twenty-four hours after transfection, the medium was replaced with serum-containing DMEM. After 24 h, each virus-containing supernatant was mixed and used for retroviral infection. Concerning iPSCs generation, TTFs were isolated from adult Nanog-GFP-IRES-Puro<sup>r</sup> reporter mice or adult DsRed-transgenic mice. For the four-factor transduction, retrovirus-containing supernatants for *Klf4*, *c-Myc*, *Oct3/4*, *Sox2* and *DsRed*, were mixed with the ratio of 1:1:1:1:4. When the fibroblasts were transduced with the three factors, retrovirus-containing supernatants for *Klf4*, *Oct3/4*, *Sox2*, *DsRed* and Mock were mixed with the ratio of 1:1:1:1:4. For transfection, TTFs were seeded at  $8.0 \times 10^5$  cells in 100-mm dish, without feeder cells. TTFs were incubated in the virus/polybrene-containing supernatants for 24 h. Four days after transduction, TTFs transduced with the three factors were reseeded at  $3.5 \times 10^5$  cells per 100-mm dish with SNL feeder

**Fig. 1** Comparison of five iPSC lines during EB culture. **a** TTF-derived iPSCs. Morphology of five iPSC lines maintained on mitomycin-C (MMC)-treated mouse embryonic fibroblasts (MEFs) is shown by phase contrast and DsRed or GFP fluorescence. 256H13 and 256H18 iPSCs constitutively express DsRed under control of the  $\beta$ -actin (*Actb*) promoter, while 212B2, 212D1 and 335D1 iPSCs express GFP under control of the *Nanog* promoter. Scale bars are 200  $\mu$ m. **b** Cell morphology during iPSC differentiation. Differentiation of iPSCs at days 4, 5, and 6. Phase contrast images. Scale bars are 100  $\mu$ m. **c** Total number of viable cells from each of five lines during the course of EB formation. Four, five and six days after EB formation, differentiated-iPSCs were collected and viable cells counted using Trypan blue dye




cells and cultured with ES medium containing DMEM, 15% FBS, 0.1 mM non essential amino acid, 0.1 mM 2-mercaptoethanol (2-ME) and 1000U/ml mouse leukemia inhibitory factor (LIF). TTFs transduced with the four factors were reseeded at  $0.5 \times 10^5$  cells per 100-mm dish with feeder cells. Thirty to forty days after transduction, the colonies were selected for expansion. Drug selection with puromycin (1.5  $\mu$ g/ml) was done for 212B2, 212D1 and 335D1 iPSCs. 256H13 and 256H18 iPSC lines were established without drug selection [6]. Twenty to thirty percent efficiency was achieved in transfection of all five iPSC lines.

We firstly expanded these iPSC lines with mitomycin-C (MMC)-treated mouse embryonic fibroblasts (MEFs) in StemMedium (DS Pharma Biomedical, Hyogo, Japan) containing 0.1 mM 2-ME (Nacalai Tesque, Inc., Kyoto, Japan) and 1000 U/ml mouse LIF (prepared in Dr. Minetaro Ogawa's Laboratory). The passage number (P) for each line used in this study was as follows; 256H13 (P.6-P.9), 256H18 (P.8-P.10), 212B2 (P.9), 212D1 (P.6), and 335D1 (P.8-P.10).

### Embryoid Body (EB) Formation

Before EB formation, iPSCs were separated from feeder cells by 0.5-hour incubation to eliminate the attached MEF cells. Then, iPSCs expressing stage-specific embryonic antigen-1 (SSEA-1) were purified by magnetic cell separation (MACS, Miltenyi Biotec, Auburn, CA). iPSCs ( $6 \times 10^4$  cells) were cultured in 3 ml of EB medium, which contains Iscove's Modified Dulbecco's Medium (IMDM, SIGMA-ALDRICH, St. Louis, MO) containing 15% FBS (a pre-selected batch showing the highest efficiency in inducing hematopoietic cells), 2 mM L-glutamine (SIGMA-ALDRICH), 0.0026% (vol/vol) monothioglycerol (MTG; Wako Pure Chemical Industries, Osaka, Japan), 50  $\mu$ g/ml L-ascorbic acid (Wako Pure Chemical Industries), 10 U/ml penicillin, and 10  $\mu$ g/ml streptomycin (SIGMA-ALDRICH).

For mesodermal cell differentiation, no cytokine was added in the EB medium. Petri dishes (60-mm in diameter, Kord-Valmark™, Ontario, Canada) were used to generate EBs. On culture days 4, 5, and 6, cells were collected by gentle pipetting, washed once in PBS, and then incubated in



Cell Dissociation Buffer (Life Technologies, Carlsbad, CA) at 37°C for 30 min. An equal volume of medium containing 10% FBS was added and mixed gently by pipetting, and the cell suspension was passed through a 40- $\mu$ m nylon mesh. The number of living cells was determined by staining with 0.4% Trypan blue (Life Technologies). For hematopoietic cell differentiation, SCF (stem cell factor), IL (interleukin)-3, EPO (erythropoietin), IL-6 and G-CSF (granulocyte colony-stimulating factor) were added in the EB medium. Petri dishes were used to generate EBs. On culture days 9, cells were collected and counted as mentioned above.

### Flow Cytometry

To analyze mesodermal cells from iPSCs, cells cultured for 4, 5, and 6 days were collected as mentioned in 'EB formation' and stained with an APC-conjugated anti-CD324 (E-cadherin) antibody (Ab) (Alexa Fluor®647, eBioscience, San Diego, CA), a Pacific Blue™-conjugated anti-mouse Flk1 (VEGFR2) Ab (BioLegend, San Diego, CA), a biotin-conjugated anti-mouse CD140 $\alpha$  (PDGFR $\alpha$ ) Ab (eBioscience) and an APC-Cy7-conjugated streptavidin (BD Biosciences, San Jose, CA). Biotin-conjugated antibody was used as a primary antibody and fluorescence-conjugated streptavidin was used as a secondary reagent, respectively. E-cadherin/Flk1<sup>+</sup> cells were defined as lateral mesodermal cells and E-cadherin/PDGFR $\alpha$ <sup>+</sup> cells as paraxial mesodermal cells, respectively.

To analyze hematopoietic cells from iPSCs, cells cultured for 9 days were collected as mentioned in 'EB formation' section and stained with an APC-Cy7-conjugated anti-mouse Ter119 Ab (eBioscience), a PB-conjugated anti-mouse CD45 Ab (BioLegend), an APC-conjugated anti-mouse F4/80 (BioLegend), a biotin-conjugated anti-mouse Gr-1 Ab (eBioscience) and PE-Cy7-conjugated streptavidin (BD Biosciences). For Mac1 Ab, a PE-conjugated anti-mouse Mac1 Ab (BioLegend) was used for GFP-expressing iPSCs (212B2, 212D1, and 335D1). And a biotin-conjugated anti-mouse Mac1 Ab (eBioscience) and a PE-Cy7-conjugated streptavidin were used for DsRed-expressing iPSCs, respectively. Biotin-conjugated antibody was used as a primary antibody and fluorescence-conjugated streptavidin was used as a secondary reagent, respectively. Ter119 positive cells were defined as erythroid cells, CD45 positive cell as leukocytes, Mac1<sup>+</sup>/F4/80<sup>+</sup> cells as macrophages and Gr-1<sup>+</sup>/F4/80<sup>-</sup> cells as granulocytes, respectively.

To stain dead cells, propidium iodide (PI, Life Technologies, Eugene, Oregon) was used for GFP-expressing iPSCs, and TO-PRO®-1 iodide (Life Technologies) was used for DsRed-expressing iPSCs. Cells were analyzed using a FACS Aria cell sorter (Becton Dickinson, Franklin Lakes, NJ). Data files were analyzed using FlowJo software (Tree Star, San Carlos, CA).

**Fig. 2** Mesodermal cell differentiation from iPSCs. **a** Flow cytometric analysis of mesodermal cells from all five iPSC lines at days 4, 5, and 6 during the course of EB culture. Lateral mesodermal cells were evaluated based on lack of expression of the surface marker E-cadherin (CD324, epithelial cadherin) and expression of Flk1 (CD309, VEGFR2) (*upper panel*). Paraxial mesodermal cells were evaluated based on lack of expression of E-cadherin and expression of PDGFR $\alpha$  (*lower panel*). **b** Quantitative real-time PCR analysis was used to detect the mesodermal markers *Flk1*, *Tbx6* and *Brachyury* at day 4 of EB culture. Data was normalized to  $\beta$ -actin expression

### Quantitative Real-Time PCR


Total RNA was isolated with the RNAqueous-Micro Kit (Ambion, Austin, TX). A high-capacity cDNA Archive kit (Applied Biosystems, Foster City, CA) was used to synthesize cDNA from mRNA. mRNA levels were normalized to  $\beta$ -actin as an internal control. In real-time PCR, mRNA levels were analyzed by the SYBR Green method with gene-specific primers or Taqman probe methods. Genes analyzed by SYBR Green included *Oct3/4* (Fw; gcagctcagccttaagaacatgt, Rv; cgattgcatatctcctgaaggt), *Klf4* (Fw; gaactcacacagcgagaaacc, Rv; tcggagcggcgcaatt), *Sox2* (Fw; atcaggctgctcgagaatcc, Rv; ctcaactgtgcataatggagt taaaaa) and *Nanog* (Fw; caaaccaaaggatgaagtgcac, Rv; gtgctgagccctctgatca). *Oct3/4*, *Klf4*, and *Sox2* primer sets recognized both internal and external sequences. Mouse  $\beta$ -actin (Fw; gctctgctctagcaccat, Rv; gccaccgatccacacagat) served as an internal control. Genes analyzed using the Taqman probe (Applied Biosystems) included *Flk1* (Mm01222421\_m1), *Brachyury* (Mm01318252\_m1), *Tbx6* (Mm00441681\_m1), *Gata1* (Mm01352636\_m1), *Klf1* (Mm00516096\_m1), *CD45* (Mm01293577\_m1), *Csf1r* (Mm01266652\_m1), *PU.1* (Mm00488142\_m1), and *c-Myc* (Mm00487804\_m1). Mouse  $\beta$ -actin (4352933E) served as an internal control.

## Results


### Morphology and EB Formation Capacity of TTF-derived iPSCs

In this study, we cultured 5 induced pluripotent stem cell (iPSC) lines—256H13, 256H18, 212B2, 212D1, and 335D1—which were established by different protocols from adult mouse tail-tip fibroblasts (TTF) [6]. The *DsRed* gene is downstream of the  $\beta$ -actin (*ACTB*) gene in 256H13 and 256H18 iPSCs, whereas *GFP* is downstream of *Nanog* and serves an indicator of pluripotency in 212B2, 212D1, and 335D1 iPSCs, as summarized in Fig. 1a. *Oct3/4*, *Klf4*, and *Sox2* genes were transduced into TTFs to establish all iPSC lines, while the 212B2 line was also transduced with *c-Myc*. All iPSC colonies exhibited round morphology and exhibited large nucleoli and low cytoplasmic content.

**a**



**b**



335D1 formed larger colonies than other lines (Fig. 1a). 212B2, 212D1 and 335D1 lines were GFP-positive, indicative of *Nanog* expression and pluripotency.

Next, we performed differentiation culture using the method of embryoid body (EB) formation without cytokines (Supplementary Fig. 1a). Four, five and six days after EB formation, we observed the cultured cells microscopically (Fig. 1b) and evaluated proliferation by cell counting (Fig. 1c). All iPSCs formed EBs, although EB size and the number of adherent cells varied among lines (Fig. 1b). 212B2 and 335D1 iPSCs formed round EBs, although 335D1-derived EBs were larger than 212B2-derived EBs. By contrast, cultured 256H13, 256H18 and 212D1 iPSCs gave rise to adherent cells as well as round EBs. 256H18-derived EBs were larger than those derived from 212D1 cells at day 5 and, in the case of 256H18, adherent cells were observed most frequently (Fig. 1b). In terms of proliferation, the number of 256H13-derived cells increased at day 4 ( $2.75 \times 10^5$  cells) and then plateaued. The number of 256H18 iPSCs also increased gradually through the culture period and then plateaued. 256H18 iPSCs-derived cells gradually increased during the culture and plateaued at day 5 ( $4.70 \times 10^5$  cells). Although 212B2 and 335D1 lines increased gradually during the culture period, their viable cell number at day 6 ( $1.69 \times 10^5$  and  $3.63 \times 10^5$ , respectively) was lower than that of 256H18 iPSCs. By contrast, the number of 212D2-derived cells increased from day 4 ( $5.50 \times 10^4$  cells) to 5 ( $1.70 \times 10^5$  cells), and then decreased ( $1.19 \times 10^5$  cells). There was no significant difference among all iPSC lines in cell viability during EB culture (Supplementary Fig. 2). Taken together, our results indicate that EB formation and cell proliferation varies among five iPSC lines derived from the same tissue.

#### Mesodermal Potential of TTF-derived iPSCs







To assess iPSC hematopoietic potential, we first examined their mesodermal potential, as hematopoietic cells are mesodermal in origin [13, 14]. ESC mesodermal differentiation was monitored using three markers: lack of E-cadherin (a marker of both ectoderm and endoderm in early mouse development [15]) expression, expression of platelet-derived growth factor receptor  $\alpha$  (PDGFR $\alpha$ ) and Flk1 (also known as VEGF receptor 2) [16, 17]. We compared the number of iPSC-derived E-cadherin<sup>-</sup>/Flk1<sup>+</sup> cells, representing lateral mesoderm, and E-cadherin<sup>-</sup>/PDGFR $\alpha$ <sup>+</sup> cells, representing paraxial mesoderm, at days 4, 5 and 6 of EB culture, since ESC-derived EBs [18, 19] contain Flk1<sup>+</sup> mesodermal cells at 4 to 4.5 days of culture and iPSC-derived EBs contain Flk1<sup>+</sup> cells at 5 days of culture [12]. The emergence of E-cadherin<sup>-</sup>/Flk1<sup>+</sup> cells from the 256H13 line was the most rapid among the five lines tested, and the number of cells in this fraction was highest at day 4 (193 cells) and then decreased (Fig. 2a,

**Fig. 3** Hematopoietic cell differentiation from iPSCs. **a** Differentiated iPSCs were collected at day 9 of EB culture and Ter119<sup>+</sup> erythroid cells were evaluated by flow cytometry. **b** Quantitative real-time PCR analysis was used to detect expression of the erythroid genes *Gata1* and *Klf1* at day 9 of EB culture. Data was normalized to  $\beta$ -actin expression. **c, d** Differentiated iPSCs were collected at day 9 of EB culture and evaluated by flow cytometry for (c) CD45<sup>+</sup> leukocytes and (d) myeloid cells (Mac1<sup>+</sup>/F4/80<sup>+</sup> macrophages and Gr-1<sup>+</sup>/F4/80<sup>+</sup> granulocytes). **e** Quantitative real-time PCR analysis was used to detect expression of the myeloid-related genes *CD45*, *Csf1r* and *PU.1* at day 9 of EB culture. Data was normalized to  $\beta$ -actin expression

upper panel). The number of E-cadherin<sup>-</sup>/Flk1<sup>+</sup> cells from 256H18 was the highest among the five lines tested (day 5; 776 cells) (Fig. 2a, upper panel). In contrast, the number of 212B2 and 212D1 iPSC-derived E-cadherin<sup>-</sup>/Flk1<sup>+</sup> cells was lower than that seen in the other three lines. The number of E-cadherin<sup>-</sup>/PDGFR $\alpha$ <sup>+</sup> cells from 256H18 was highest among the five lines (day 6;  $3.97 \times 10^5$  cells) (Fig. 2a, lower panel). The number of E-cadherin<sup>-</sup>/PDGFR $\alpha$ <sup>+</sup> cells from 256H13 and 212D1 lines increased from days 4 to 5 and then decreased, whereas those from 256H18 and 212B2 lines gradually increased from days 4 to 6. The number of E-cadherin<sup>-</sup>/PDGFR $\alpha$ <sup>+</sup> cells from 335D1 dramatically increased from day 5 ( $1.59 \times 10^4$  cells) to day 6 ( $1.10 \times 10^5$  cells) (Fig. 2a, lower panel). To confirm iPSC mesodermal cell differentiation, we employed PCR to examine expression of the mesoderm markers *Flk1* (lateral mesoderm), *Tbx6* [20] (paraxial mesoderm) and *Brachyury* [21] (pan-mesodermal marker). *Flk1* expression was lowest in 256H13-derived cells at day 4 of culture (Fig. 2b), whereas it was highest in 256H18-derived cells over days 4 to 6 (Supplementary Fig. 3 and 5). *Tbx6* expression at day 4 was highest in 256H18-derived iPSCs, whereas *Tbx6* expression was highest at days 5 and 6 in 335D1- and 256H13-derived cells, respectively (Fig. 2b and Supplementary Fig. 3 and 5). *Brachyury* expression at day 4 was higher in 256H18- and 335D1-derived cells compared to others (Fig. 2b), whereas it was highest at days 5 and 6 in 335D1- and 256H13-derived cells, similar to *Tbx6* expression (Supplementary Fig. 3 and 5). There was a trend in mesodermal differentiation. Early differentiation in 256H13 cells was observed, whereas late differentiation in 335D1 (Fig. 2a). 256H18 cells differentiated into both lateral and paraxial mesoderm most frequently. Overall differences we observed in mesodermal differentiation potential suggest variation in mesodermal potential of adult skin-derived induced pluripotent stem cell lines in mice.

#### Hematopoietic Potential of TTF-derived iPSCs

Next we examined cell number and the percentage of erythroid and myeloid cells emerging during EB formation at day 9 of culture in the presence of cytokines (Supplementary Fig. 1b). Flow cytometry analysis showed that








Fig. 3 (continued)


lines 256H18 and 335D1 efficiently differentiated into Ter119<sup>+</sup> erythroid cells at 0.35% (1280 cells) and 0.72% (1991 cells), respectively. By contrast, 212B2 cells differentiated into Ter119<sup>+</sup> cells at low frequency (46 cells, 0.12%) (Fig. 3a, Supplementary Fig. 4a). In agreement, real-time PCR analysis showed that expression of the erythropoietic transcription factors *Gata1* [22] and *Klf1* [23] was the highest in 335D1 cells (6.05 times higher than in 212D1 cells and 3.07 times higher than in 256H13 cells) (Fig. 3b). 256H18 and 335D1 cells differentiated into CD45<sup>+</sup> leukocytes at 1.32% (4880 cells) and 1.17% (3229 cells), respectively (Fig. 3c, Supplementary Fig. 4b).

Flow cytometry analysis showed that 256H18 cells differentiated into Mac1<sup>+</sup>/F4/80<sup>+</sup> macrophages at high frequency (3622 cells, 0.98%) (Fig. 3d, left panel; Supplementary Fig. 4c, left panel), whereas 335D1 cells differentiated into Gr-1<sup>+</sup>/F4/80<sup>+</sup> granulocytes at high frequency (6738 cells, 2.45%) (Fig. 3d, right panel; Supplementary Fig. 4c, right panel). By contrast, 212B2 cells, which are transduced with the *c-Myc* gene, differentiated into CD45<sup>+</sup> leukocytes, Mac1<sup>+</sup>/F4/80<sup>+</sup> macrophages and Gr-1<sup>+</sup>/F4/80<sup>+</sup> granulocytes at low frequency (523, 20 and 756 cells, respectively) (Fig. 3c, d). When we

analyzed expression of the leukocyte marker *CD45*, *Csf1r* (encoding colony stimulating factor 1 receptor, a macrophage marker), and *PU.1* (also known as *Spi-1*, which marks the myeloid lineage) at culture day 9, no significant differences were observed among the five lines (Fig. 3e). Taken together, among the five iPSC lines tested, only 256H18 and 335D1 were capable of differentiating at high frequency into both erythroid cells and leukocytes at day 9 of culture.

#### Expression of Reprogramming and Pluripotency Genes During EB Formation from iPSCs

We next investigated whether pluripotency of iPSCs was related to the nature reprogramming factors used transduce somatic cells. Prior to initiating EB culture, *c-Myc* expression was highest in 212B2 cells, which had been transduced with *c-Myc* along with *Oct3/4*, *Klf4* and *Sox2* genes (Fig. 4a). *Oct3/4* gene expression was highest in 256H13 cells, whereas *Klf4*, *Sox2* and *Nanog* gene expression did not significantly differ among the lines prior to culture. *Oct3/4*, *Klf4* and *Sox2* expression at day 4 of culture was the highest in 212B2 cells, suggesting that they retain pluripotency longer than do the other lines (Fig. 4b).



**Fig. 4** Comparison of reprogramming and pluripotency gene expression. Quantitative real-time PCR analysis was used to detect expression of the reprogramming genes *Oct3/4*, *Klf4*, *Sox2* and *c-*

*Myc* and the pluripotency gene *Nanog* at days 0 (a) and 4 (b) of EB culture. Data was normalized to  $\beta$ -actin expression

## Discussion

iPSCs constitute important tools for future regenerative medicine. In this study we compared mesodermal and hematopoietic potential of several iPSC lines, since differentiation potential reportedly varies among iPSC lines established by different sources and methods [12]. Although all iPSCs possessed pluripotency, as defined by expression of *Oct3/4* and *Nanog*, each line showed variations in EB formation and cell proliferation. Examination of mesodermal potential using both flow cytometry and real-time PCR methods, confirmed these differences: specifically, the 256H18 iPSC line gave rise to mesodermal cells at high frequency, whereas 212B2 cells showed the lowest frequency. To identify factors underlying mesodermal potential, we compared expression of both differentiation and pluripotency markers. As summarized in Supplementary Fig. 5, expression of the differentiation markers *Flk1*, *Tbx6*, and *Brachyury* in 256H18 iPSCs was highest at day 4 of culture. Although there was no significant correlation between mesodermal potential and expression of pluripotency markers (Fig. 4), the number of EBs is likely positively correlated with mesodermal potential (Fig. 1). In terms of hematopoietic potential, variations in differentiation capacity were confirmed by flow cytometric and real-time PCR analyses. 256H18 and 335D1 iPSCs generated erythroid cells and leukocytes at high frequency, whereas a low frequency was seen with 212B2 cells (Fig. 3). Expression of the *Oct3/4*, *Sox2*, *Klf4* and *Nanog* pluripotency genes in 256H18 was lowest, whereas 212B2 iPSCs showed highest expression of *Oct3/4*, *Sox2* and *Klf4*. Given the results of our hematopoietic cell differentiation assays at day 4 of culture, these results suggest an inverse relationship between hematopoietic potential and pluripotency gene expression (Fig. 4). *c-Myc* expression in 212B2 cells was highest before culture (Fig. 4a), likely due to ectopic transduction of *c-Myc*. There was a correlation between high *c-Myc* expression and low induction of mesodermal and hematopoietic cells. In our culture conditions, *c-Myc* likely down-regulates mesodermal and hematopoietic cell induction from the 212B2 iPSC line. Our results are compatible with previous reports mentioning that *c-Myc* maintains pluripotency of ESCs [24] and iPSCs [25], and similar to the report showing that *c-Myc* down-regulates cardiogenic [26] and endodermal differentiation [25] of iPSCs. Taken together, our results imply that iPSCs lacking *c-Myc* transduction will be preferably used for clinical purposes.

Passage number of iPSCs reportedly affected the hematopoietic differentiation [27]. As passage number of iPSCs increased, the transient epigenetic memory of their original somatic cells was gradually lost and hematopoietic differentiation capacity was up-regulated in TTF-derived iPSCs [27]. 256H18 and 335D1 iPSCs generated hematopoietic cells at high frequency, whereas a low frequency was seen in 212B2 in our culture condition (Fig. 3). Since we used iPSC

lines of 256H18, 335D1 and 212B2 with similar passage number (P.8- P.10), it is unlikely that passage number affected the hematopoietic differentiation capacity among these three lines. Concerning the other 2 iPSC lines, passage number was lower in 256H13 (P.6-P.9) and 212D1 (P.6) than in 256H18, 335D1 and 212B2. Less hematopoietic cell differentiation in 256H13 and 212D1 than 256H18 and 335D1 was might be due to the difference of passage number.

Taken together, even derived from the same TTF origin, each iPSC demonstrated different mesodermal and hematopoietic potential. Transduction method with retroviral infection and transfection efficiency (20–30%) were similar, while *c-Myc* gene transduction, drug selection with puromycin, reporter genes (Actb-DsRed or Nanog-GFP) and passage number were not identical among five iPSC lines. Therefore, variation in mesodermal and hematopoietic potential was likely affected by combination of transduced genes and passage number, but not transfection methods, drug selection and reporter genes.

Recently, it was reported that iPSCs can be established from peripheral blood (PB) cells [28]. Since collecting a PB sample from a patient is practically easier than taking skin fibroblasts by biopsy in terms of risk and pain, it will be further necessary to evaluate the hematopoietic potential of PB-derived iPSCs in both mice and humans.

**Acknowledgements** This work was supported by a grant from the Project for Realization of Regenerative Medicine from the Ministry of Education, Culture, Sports, Science and Technology and by a grant from the BASIS project from the Ministry of Education, Culture, Sports, Science and Technology. T. Inoue and K. Kulkeaw is supported by research fellowships from the Ministry of Education, Culture, Sports, Science and Technology, and from The Tokyo Biochemical Research Foundation, respectively. We thank Dr. Keisuke Okita, Ms. Yuka Horio, Ms. Chiyo Mizuochi and the Research Support Center, Graduate School of Medical Sciences, Kyushu University for technical supports, and Dr. Minetaro Ogawa and Dr. Hiroshi Sakamoto for providing LIF. All iPSCs were kindly provided by Dr. Shinya Yamanaka.

**Author Contributions** Tomoko Inoue performed the experiments, analyzed data and wrote the manuscript. Kasem Kulkeaw, Satoko Okayama and Kenzaburo Tani performed the experiments. Daisuke Sugiyama designed the experiments and wrote the manuscript.

**Conflict of Interest** All disclosures will be published when the manuscript is accepted.

## References

1. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*, 126, 663–676.
2. Wernig, M., Meissner, A., Foreman, R., et al. (2007). In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. *Nature*, 448, 318–324.

3. Okita, K., Ichisaka, T., & Yamanaka, S. (2007). Generation of germline-competent induced pluripotent stem cells. *Nature*, *448*, 313–317.
4. Yu, J., Vodyanik, M. A., Smuga-Otto, K., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. *Science*, *318*, 1917–1920.
5. Nelson, T. J., Martinez-Fernandez, A., Yamada, S., Mael, A. A., Terzic, A., & Ikeda, Y. (2009). Induced pluripotent reprogramming from promiscuous human stemness related factors. *Clinical and Translational Science*, *2*, 118–126.
6. Nakagawa, M., Koyanagi, M., Tanabe, K., et al. (2008). Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. *Nature Biotechnology*, *26*, 101–106.
7. Stadtfeld, M., Brennand, K., & Hochedlinger, K. (2008). Reprogramming of pancreatic beta cells into induced pluripotent stem cells. *Current Biology*, *18*, 890–894.
8. Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., & Yamanaka, S. (2008). Generation of mouse induced pluripotent stem cells without viral vectors. *Science*, *322*, 949–953.
9. Aoi, T., Yae, K., Nakagawa, M., et al. (2008). Generation of pluripotent stem cells from adult mouse liver and stomach cells. *Science*, *321*, 699–702.
10. Hanna, J., Markoulaki, S., Schorderet, P., et al. (2008). Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. *Cell*, *133*, 250–264.
11. Takenaka, C., Nishishita, N., Takada, N., Jakt, L. M., & Kawamata, S. (2010). Effective generation of iPS cells from CD34+ cord blood cells by inhibition of p53. *Experimental Hematology*, *38*, 154–162.
12. Kulkeaw, K., Horio, Y., Mizuuchi, C., Ogawa, M., & Sugiyama, D. (2010). Variation in hematopoietic potential of induced pluripotent stem cell lines. *Stem Cell Reviews*, *6*, 381–389.
13. Huber, T. L., Kouskoff, V., Fehling, H. J., Palis, J., & Keller, G. (2004). Haemangioblast commitment is initiated in the primitive streak of the mouse embryo. *Nature*, *432*, 625–630.
14. Lengerke, C., Grauer, M., Niebuhr, N. I., et al. (2009). Hematopoietic development from human induced pluripotent stem cells. *Annals of the New York Academy of Sciences*, *1176*, 219–227.
15. Era, T., Izumi, N., Hayashi, M., Tada, S., & Nishikawa, S. (2008). Multiple mesoderm subsets give rise to endothelial cells, whereas hematopoietic cells are differentiated only from a restricted subset in embryonic stem cell differentiation culture. *Stem Cells*, *26*, 401–411.
16. Kataoka, H., Takakura, N., Nishikawa, S., et al. (1997). Expressions of PDGF receptor alpha, c-Kit and Flk1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells. *Development, Growth & Differentiation*, *39*, 729–740.
17. Sakurai, H., Era, T., Jakt, L. M., Okada, M., Nakai, S., & Nishikawa, S. (2006). In vitro modeling of paraxial and lateral mesoderm differentiation reveals early reversibility. *Stem Cells*, *24*, 575–586.
18. Choi, K., Kennedy, M., Kazarov, A., Papadimitriou, J. C., & Keller, G. (1998). A common precursor for hematopoietic and endothelial cells. *Development*, *125*, 725–732.
19. Fehling, H. J., Lacaud, G., Kubo, A., et al. (2003). Tracking mesoderm induction and its specification to the hemangioblast during embryonic stem cell differentiation. *Development*, *130*, 4217–4227.
20. Chapman, D. L., Agulnik, I., Hancock, S., Silver, L. M., & Papaioannou, V. E. (1996). Tbx6, a mouse T-Box gene implicated in paraxial mesoderm formation at gastrulation. *Developmental Biology*, *180*, 534–542.
21. Wilkinson, D. G., Bhatt, S., & Herrmann, B. G. (1990). Expression pattern of the mouse T gene and its role in mesoderm formation. *Nature*, *343*, 657–659.
22. Whitelaw, E., Tsai, S. F., Hogben, P., & Orkin, S. H. (1990). Regulated expression of globin chains and the erythroid transcription factor GATA-1 during erythropoiesis in the developing mouse. *Molecular and Cellular Biology*, *10*, 6596–6606.
23. Miller, I. J., & Bieker, J. J. (1993). A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Kruppel family of nuclear proteins. *Molecular and Cellular Biology*, *13*, 2776–2786.
24. Varlakhanova, N. V., Cotterman, R. F., & deVries, W. N. (2010). Myc maintains embryonic stem cell pluripotency and self-renewal. *Differentiation*, *80*, 9–19.
25. Smith, K. N., Singh, A. M., & Dalton, S. (2010). Myc represses primitive endoderm differentiation in pluripotent stem cells. *Cell Stem Cell*, *7*, 343–54.
26. Martinez-Fernandez, A., Nelson, T. J., Ikeda, Y., & Terzic, A. (2010). c-MYC independent nuclear reprogramming favors cardiogenic potential of induced pluripotent stem cells. *Journal of Cardiovascular Translational Research*, *3*, 13–23.
27. Polo, J. M., Liu, S., & Figueroa, M. E. (2010). Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. *Nature Biotechnology*, *28*, 848–855.
28. Loh, Y. H., Agarwal, S., & Park, I. H. (2009). Generation of induced pluripotent stem cells from human blood. *Blood*, *113*, 5476–9.